Table 1.

Demographic and clinic patient characteristics, 2001–2017. ART, antiretroviral; ART-NP, antiretroviral-naïve patients; ART-EP, antiretroviral-experienced patients.

Patient Characteristics	ART-NP	ART-EP
Total, n (%)	7310 (100%)	3848 (100%)
Sex, n (%)
Female	2521 (34.5%)	1239 (32.2%)
Male	4719 (64.6%)	2588 (67.3%)
Median age at genotyping in years (IQR)	38.0 (31.0–48.0)	39.0 (33.0–46.0)
18–25	766 (10.5%)	153 (4.0%)
26–40	3287 (45.0%)	1930 (50.2%)
41–55	2263 (31.0%)	1366 (35.5%)
>56	843 (11.5%)	340 (8.8%)
Mode of transmission, n (%)
Heterosexuals	358 (4.9%)	181 (4.7%)
Men who have sex with men	193 (2.6%)	69 (1.8%)
Intravenous drug use	189 (2.6%)	173 (4.5%)
Others	78 (1.1%)	106 (2.8%)
Unknown	6492 (88.8%)	3319 (86.3%)
Region of origin, n (%)
Portugal	2535 (34.7%)	1152 (29.9%)
Sub-Saharan Africa	972 (13.3%)	427 (11.1%)
South America	201 (2.8%)	46 (1.2%)
Europe	81 (1.1%)	20 (0.5%)
Others	10 (0.1%)	4 (0.1%)
Unknown	3511 (48.0%)	2199 (57.2%)
Year of genotyping, n (%)
2001–2005	655 (9.0%)	1555 (40.4%)
2006–2009	1812 (24.8%)	1226 (31.9%)
2010–2013	2270 (31.1%)	588 (15.3%)
2014–2017	2573 (35.2%)	479 (12.4%)
HIV-1 subtype, n (%)
Subtype B	2686 (36.7%)	1639 (42.6%)
Subtype G	1845 (25.2%)	1262 (32.8%)
Subtype C	499 (6.8%)	149 (3.9%)
Subtype A	312 (4.3%)	55 (1.4%)
Subtype F1	265 (3.6%)	72 (1.9%)
Circulating Recombinants Forms (CRFs)	1621 (22.2%)	635 (16.5%)
Other HIV-1 subtypes	67 (0.92%)	28 (0.7%)
CD4 count at time of resistance test (cells/mL)
Median CD4 count (IQR; range)	321.5 (145.0–505.0) (0.0–1905.0)	262.0 (136.0–440.0) (0.0–1844.0)
<50	415 (5.7%)	308 (8.0%)
51–200	762 (10.4%)	868 (22.6%)
201–350	807 (11.0%)	817 (21.2%)
351–500	735 (10.1%)	533 (13.9%)
501	929 (12.7%)	565 (14.7%)
Unknown	3662 (50.1%)	757 (19.7%)
Viral Load at time of resistance test (log10 copies/mL)
Median Log Viral Load (IQR)	4.8 (4.2–5.4)	4.2 (3.5–4.8)
<4.0	1111 (15.2%)	1526 (39.7%)
4.1 to 5.0	2354 (32.2%)	1227 (31.9%)
>5.1	2187 (29.9%)	620 (16.1%)
Unknown	1658 (22.7%)	475 (12.3%)